Beatrix Oppenberg Ph.D., Mba

Beatrix Oppenberg has extensive work experience in the pharmaceutical and biotech industries. Beatrix Oppenberg currently holds the position of CMC Director at Versameb AG. Prior to this, they worked as a Senior Project Manager at NovaGo Therapeutics from 2020 to 2022. Beatrix also served as an MSAT Quality Risk Management Consultant at Roche from 2019 to 2020 and as a Senior Program Manager Bioconjugates at Lonza from 2018 to 2019. Beatrix Oppenberg has held positions such as Senior Project Leader at Celonic Group from 2014 to 2018 and Project Manager (Temporary Contractor) at Roche from 2013 to 2014. Additionally, Beatrix has experience as a Project Leader at Pevion Biotech AG from 2012 to 2013, a Technical Project Leader at Vifor Pharma (International) Ltd from 2010 to 2012, a Project Manager Pharmaceutical Development at Eidetica Biopharma AG from 2010 to 2010, and a Project Director Quality Assurance and Regulatory Affairs at Finox AG from 2008 to 2009. With a PhD, MBA, and PMP certification, Beatrix Oppenberg brings a strong background and expertise to their roles in the industry.

Beatrix Oppenberg holds a PhD in Biology from the University of Zurich, which they obtained from 1986 to 1991. In addition, they earned a Master of Business Administration (exec.MBA-HSG) from the University of St.Gallen, completing their studies from 1996 to 1998.

In terms of additional certifications, Beatrix Oppenberg has obtained several qualifications. In 2013, they earned the Project Management Professional (PMP) certification from the Project Management Institute. In 2016, they achieved the GMP Compliance Manager certification from CONCEPT HEIDELBERG GmbH and the ECA Certified Biotech Manager certification from ECA Foundation & ECA Academy. In 2017, Beatrix Oppenberg obtained the qualification of Qualitätssicherungs - / GMP-Beauftragte in der Pharmazeutischen Industrie from CONCEPT HEIDELBERG GmbH. Furthermore, they earned a Postgraduate Certification in Clinical Trial Management from PAREXEL Academy in 2019. Most recently, in 2022, they obtained the Pharmaceutical and Medical Devices Dual Regulatory Affairs Certification Program from the Regulatory Affairs Professionals Society (RAPS).